This study demonstrated that the antitumour peptide is capable of killing tumour cells in an RGD-dependent manner, thus lowering the non-specific cytotoxic effects expected to occur when using cationic cytotoxic peptides. Thus, this chemistry is suitable for the design of complex, multifunctional molecules that can be used for both imaging and therapeutics, representing the next generation of perfectly controlled, targeted drug delivery systems.
Introduction
Selective inactivation of certain tumour-enhancing events would be expected to provide strong therapeutic benefits with the absence of detrimental side effects, as are seen with conventional chemotherapy. Examples of such targeting have been described for the treatment " "
of gastrointestinal stromal tumours, renal cell carcinoma, breast cancer, colorectal cancer and non small cell lung cancer patients -harbouring epidermal growth factor receptor (EGFR) mutations (bevacizumab and erlotinib). The new highly selective molecules that are currently being tested or have recently been proven in clinical trials are either small molecules that diffuse through virtually every cell of the body, such as tyrosine kinase inhibitors (TKI), or monoclonal antibodies that bind specifically to their target and block it. Small molecules have the disadvantage of diffusing equally well in sick and normal cells, thus causing adverse effects despite their extremely high specific activity. On the other hand, the major disadvantage associated with the use of monoclonal antibodies comes from their large size and poor diffusion within solid tumours. Additionally, this diffusion problem has also prevented the successful utilization of other targeted large molecules, such as nanoparticles.
To avoid some of the therapeutic difficulties concerning the specificity, size and diffusion of the targeted molecules, we designed a molecular scaffold with a low molecular weight called RAFT(c -RGDfK-) . This molecule (RAFT-RGD) binds to and is endocytosed by [ ] 4 tumour cells that overexpress the integrin a receptor that is easily accessible to the peptide because it is largely expressed on the α v β 3, surfaces of both the tumour blood vessels and tumour cells themselves. We already presented evidence that the RAFT-RGD molecule specifically targeted the integrin and , was rapidly endocytosed and facilitated preclinical tumour detection using
in vitro in vivo nuclear or optical imaging methods ( , Jin et al., 2006 Jin et al., 2007 Sancey et al., 2007 Ahmadi et al., 2008 Foillard et al., 2009 These properties of RAFT-RGD make it a suitable vector for image-guided surgery of tumours Sancey et al., 2007 . Ahmadi et al., 2008 Sancey et al., 2009a Because RAFT-RGD is rapidly internalized via the receptor in clathrin-coated small acidic vesicles ( ), we α v β 3 Sancey et al., 2009b decided to use it as a drug delivery system. Using an activatable disulfide bridge ( ), we linked the proapoptotic Razkin et al., 2006 (KLAKLAK) , (KLA) toxic peptide to the RAFT scaffold ( ). KLA is a natural antibiotic with an amphipathic
In the present study, we demonstrate the ability of RAFT-RGD to specifically carry and release a functional KLA peptide into three different cell lines , leading to mitochondrial depolarization. Using a quenched fluorescent probe, the distribution and subcellular in vitro release of the active KLA peptide can be followed using optical molecular imaging and . In addition, we show that repeated in vitro in vivo intraperitoneal injections of RAFT-RGD-KLA significantly reduced the growth rate of remote subcutaneous tumours, confirming the capacity of the RAFT-RGD carrier to both target these tumours after an intraperitoneal administration and effectively deliver an active cytotoxic peptide . in vivo
Materials and Methods

RGD-Peptide Synthesis and Fluorescent Labelling
The different compounds were synthesized according to previously reported procedures ( , ). Boturyn et al., 2004 Foillard et al., 2009 The chemical structures are presented in . Four copies of the c -RGDfK-peptide were grafted onto the upper face of the cyclic Fig. 1 [ ] pentapeptide RAFT backbone. On the opposite side, the peptidic sequence (KLAKLAK) -NH (KLA) was grafted a disulfide bridge (RAFT-RAD) was also synthesized in a similar way.
Cell Lines and Culture Conditions
The cell line HEK293( ) is a stable human embryonic kidney cell line (HEK293) transfectant of the human integrin that was FBS, 50 units/ml penicillin, and 50 g/ml streptomycin. All cell lines were cultured at 37 C in a humidified 95 air/5 CO atmosphere. 
Colocalization Studies
The cells were cultured in 4-well Lab-Tek I chambered coverglass slides in the appropriate medium and kept at 37 C. Medium was°r emoved and RAFT-RGD-QSY21 -S-S-KLA-Cy5 was added at 2 M for 1 hr in DMEM without FBS and phenol red. Then red 
Proliferation Assay and Induction of Apoptosis
IGROV-1 cells were seeded at a density of 2.1 10 per cm . The following day, the media were replaced with fresh media containing 
Mitochondrial Activity: Confocal Imaging
Mitochondrial activity was assessed using the mitochondrial potential sensor JC-1 (Invitrogen). IGROV-1 cells were cultured in 4-well Lab-Tek chamber slides and starved for 30 min before the addition of RAFT-RGD-KLA at a concentration of 1 M for 30 to 60 min at 37 μ°C . JC-1 was then used as described by the manufacturer at a concentration of 10 g/ml for 10 min at 37 C. Functional mitochondria were μ°o bserved after excitation at 543 nm from 565 to 615 nm (red), whereas depolarized mitochondria were observed after excitation at 488 nm from 500 to 550 nm (green). The experiment was performed on at least 20 randomly chosen cells. Three-dimensional topographies were determined using the Topo application within the LSM510 software, and the fluorescence intensities were quantified with the threshold application within the ImageJ software. In control conditions, the mean of the fluorescence intensities was arbitrary normalized to 1 for each individual imaging, and the variations observed after RAFT-RGD-KLA treatment were statistically analysed with an unpaired t-test (Statview).
Mitochondrial Activity: FACS Analysis
Targeted delivery of a proapoptotic peptide to tumors in vivo.
J Drug Target . Author manuscript Page / 3 10 IGROV-1 cells were cultured in 6-well plates and starved for 30 min before the addition of 2 M RAFT-RGD-KLA, KLA or μ RAFT-RAD-KLA for 2 hr. The mitochondria were labelled with 10 g/ml JC-1 for 30 min at 37 C. After treatment, the cells were μ°r esuspended with trypsin and carefully washed in PBS before analysis. Strongly to weakly polarized mitochondria ratios were determined compared to control conditions and then arbitrarily normalized to 100.
Tumour Study In Vivo
Ten million IGROV-1 cells were injected subcutaneously into 6-week-old female NMRI nude mice (6 8 weeks old, Janvier, Le -Genest Saint Isle, France; n 5 to 7 mice per group). Mice in the experimental groups were injected intraperitoneally five times per week = with a total volume of 0.2 ml of PBS alone or a solution providing 0.12 mol of RAFT-RGD-KLA or RAFT-RAD-KLA per mouse until μ day 14. Tumour length and width were measured using Vernier calipers, and the tumour volume was calculated using the standard formula: length width squared 0.52 ( ). Results are expressed as tumour volume S.E.M. 
Results
RAFT-RGD-mediated delivery of KLA
The RAFT-RGD scaffold was used for the targeted delivery of the proapoptotic drug KLA into different cell lines expressing the α v β 3 integrin. KLA was covalently attached to the dye cyanine 5 (Cy5) and linked to the RAFT-RGD vector by a labile disulfide bridge. On the other side of this bridge, the RAFT-RGD moiety was coupled to QSY21 , a quencher that absorbs Cy5 fluorescence when the S-S link is
During internalization in the target cell, the disulfide link was reduced, leading to the appearance of a detectable Cy5 Fig. 1 fluorescence only after the physical separation between QSY21 and KLA-Cy5 had occurred. This molecular construction was thus used ® to follow the delivery of the KLA-Cy5 molecule. Confocal imaging done on three different cell lines indicated that RAFT-RGD was able to efficiently release KLA-Cy5 into small vesicles (red spots). Mitochondrial labelling and colocalization experiments with KLA-Cy5 demonstrated that the released peptide reached its main target, the mitochondrion, although small endocytic vesicles containing only KLA-Cy5 could still be detected. These vesicles were mostly located in the cell periphery and represented newly formed endocytotic vesicles ( ). Fig. 2 
toxicity of RAFT-RGD-KLA
In vitro
The activity of the vectorized KLA on IGROV-1 cell-proliferation and/or apoptosis was determined ( ). Cells were treated with 0 Fig. 3 to 5 M RAFT-RGD-KLA, RAFT-RAD-KLA or KLA, for 48 hr, and the number of viable cells was determined ( ). In this assay RAFT-RGD-KLA significantly enhanced apoptosis compared to all other groups (p < 0.05). These experiments on proliferation and apoptosis were also performed on the other two cell lines (TS/A-pc and HEK293( )) and produced similar results.
The mitochondrial activity in the IGROV-1 cells was then studied in the presence of RAFT-RGD-KLA at a concentration of 1 M μ using the green monomer compound JC-1. This compound fluoresces red when it is in its J-aggregated form in polarized healthy " " mitochondria ( , ), while it fluoresces green when in it is in its monomeric dispersed form, a hallmark Reers et al., 1991 Smiley et al., 1991 of the collapsing of mitochondria during apoptosis or after metabolic stress. Two hours after the addition of 1 M RAFT-RGD-KLA to the μ culture medium of the IGROV-1 cells, mitochondrial depolarization was observed ( ), as indicated by an increase in the green Fig. 4A fluorescence intensity from 1 (control condition) to 3.62 2.99 (mean of fluorescence intensity/pixel) after treatment (p < 0.05). The red ± fluorescence intensity was similar in both conditions (1 to 1.05 0.30, p 0.6).
± =
Using the same model, mitochondrial activity was studied by flow cytometry in the presence of 2 M RAFT-RGD-KLA, μ RAFT-RAD-KLA or KLA for 2 hr ( ). Mitochondrial ratios were defined as polarized ( functional mitochondria)/depolarized Fig. 4B i.e., mitochondria and normalized to 100 in the control condition. The presence of RAFT-RGD-KLA significantly decreased the mitochondrial ratio compared to the control (44.43 8.24 . 100 11.33) or RAFT-RAD-KLA-treated groups (61.01 11.29) (p < 0.01 and p < 0.05, ± vs ± ± respectively).
Reduction of tumour growth after intraperitoneal injection of RAFT-RGD-KLA in vivo
The toxicity of RAFT-RGD-KLA was confirmed on mice bearing IGROV-1 flank tumours ( ). The animals were treated in vivo with a slightly increased level of cleaved caspase-3 staining in the tumours (data not shown).
Discussion
Our aim was to demonstrate that RAFT-RGD, a multimeric targeting vector capable of detecting tumours and their metastasis ( ), can also be used for the delivery of a toxic peptide . Keramidas et al., 2010 in vivo Nanomedicine is on the cusp of being able to provide us with several types of new therapeutic systems to fight cancer. Nanoparticles are currently imparting a second life to the chemotherapeutic arsenal. Indeed, nanoparticles not only help with drug solubilisation and
bioavailability but also assist in the transport of drugs across barriers and with the release of drugs to tumour sites while sparing healthy tissues from the damage that causes the major side effects of chemotherapy. Several drugs are currently being encapsulated such as doxorubicin, paclitaxel, adryamycin and taxol (for a recent review see ). However, the tumour specificity of these Kedar et al., 2010 nanoparticles is due to the enhanced permeability and retention phenomenon (EPR effect), which allows for their passive accumulation into tumours. Specific, ligand-mediated, active targeting of nanoparticles is still a major issue, and it is possible that this cannot be expected by simply adding a tumour-specific ligand onto the surface of the particles ( ). In addition, despite some promising Ferrari, 2010 results, the delivery of large bio -drugs such as DNA, siRNA or peptides by nanoparticles is still very limited, which may be related to our " " poor ability to achieve an active targeting that would allow the binding, internalization, release and adapted intracellular trafficking of these unstable molecules. We thus choose a parallel approach, based on the use of our multifunctional tumour targeting RAFT-RGD molecule. Because it is actively internalized once attached to the integrin receptor ( ) and then releases the drug or Sancey et al., 2009b molecular probe into the cytoplasm of the target cells ( , , ) due to the presence of a Garanger et al., 2005 Jin et al., 2006 Razkin et al., 2006 labile disulfide bridge between the RAFT-RGD vector and the cargo, we hypothesized that RAFT-RGD could efficiently deliver a toxic KLA peptide to tumour cells.
RAFT-RGD-KLA allows the internalization and release of KLA into intracellular vesicles, but a fraction of the peptide can escape these vesicles and reach its main target, the mitochondria. Indeed, we observed that 90 to 95 of the mitochondria were decorated with the % Cy5-labelled KLA peptide in our conditions. In addition, the released KLA peptide was still active and toxic because it was disturbing the mitochondrial potential, as demonstrated by the membrane potential sensitive dye JC-1. At low doses, the released drug initiated mitochondrial depolarization, which could result in the inhibition of cellular proliferation and the induction of apoptosis when as little as 2.5 M of peptides was provided to the IGROV-1 human cancer cells .
The amphipathic KLA peptide not very toxic ( ). It is supposed to induce apoptosis by disrupting the Borgne-Sanchez et al., 2007 negatively charged mitochondrial membrane, but not the zwitterionic plasma membrane of eukaryotic cells. However, a very similar peptide was shown to induce also necrosis after disruption of the plasma membrane ( ). The vectorization of this Papo et al., 2006 proapoptotic peptide (or of its D-diastereomer) has previously been reported using antibody-targeted delivery ( ), fusion Marks et al., 2005 to the cell-penetrating peptide TAT ( ) or poly-arginine ( ), infection with a recombinant adenovirus Kwon et al., 2008 Law et al., 2006 vector ( ) and by fusion to a protein transduction domain ( ) or to an integrin targeting Oshikiri et al., 2006 Mai et al., 2001 α v β 3 RGD-peptide ( , ). In our experiment, the growth of human IGROV-1 xenografts was Ellerby et al., 1999 Smolarczyk et al., 2006 significantly reduced after intraperitoneal treatment with KLA (0.12 mol, daily) conjugated to RAFT-RGD.
, the reduction of natural L-diastereomers are known to lose their activity in serum and to be cleaved by trypsin and proteinase K ( ). Papo et al., 2002 Diastereomers containing L or D amino acids have several functional differences with regard to their capacity to permeate zwitterionic membranes (
). In addition, it has been shown that RGD-mediated systemic delivery of a toxic cationic peptide called Papo and Shai, 2003 tachylepsin can induce tumour killing ( ); however, its mechanism of action could be indirect and may involve the activation of the classic complement pathway (Chen et al., 2005) . For the compound used in this study, the use of an NH -protected, 2 L-isomer of KLA was found to be specific and required the binding of the molecule to its receptor because RAFT-RAD-KLA had no effect or . Thus, it is possible to rule out a non-specific mechanism of action such as complement activation or direct in vitro in vivo permeation of the plasma membrane by KLA.
RAFT-RGD was necessary to concentrate enough KLA motifs on the cell surface and to induce their internalization within clathrin-coated vesicles ( ) into which the disulfide link would be reduced and the KLA moiety released. The KLA Sancey et al., 2009b peptide could then help the molecule to destabilize the vesicles and reach the mitochondria.
, the amount of intact KLA in contact In vivo with the mitochondria was not sufficient; rather, the peptide reduced cellular proliferation by decreasing the energy supply. To augment the concentration of active peptide reaching the target cells, it would be interesting to encapsulate and protect RAFT-RGD-KLA in multi-stage delivery systems such as stealth liposomes or nanovesicles. As discussed earlier, this would allow the accumulation of a large quantity of intact RAFT-RGD-KLA by the EPR effect. When the capsule collapsed within the tumour, it would then release the targeted delivery system to the immediate vicinity of the tumour cell surface, where the RAFT-RGD would then efficiently mediate the intracellular uptake and delivery of KLA.
Thus, this study present evidence that RAFT-RGD can deliver a peptide intracellularly. This is an important proof of concept, although it is necessary to improve the overall cytotoxicity of these molecules for further possible therapeutic applications.
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